Dr Richard Barker, the former Director General of the ABPI, has been elected to the Board of Directors at biopharmaceutical company Celgene.

The experienced Dr Barker served at the ABPI for nearly seven years until his departure in May 2011, and as a board member for the European and International pharmaceutical industry federations.

Robert Hugin, Celgene’s Chairman and CEO, says Dr Barker’s “international perspective” will assist the company “through an increasingly dynamic healthcare landscape”.

The election to Celgene’s board is Dr Barker’s second appointment this month after he joined the authentication and traceability services company Aegate as a senior adviser.

Prior to Dr Barker’s time at the ABPI, he served as Chief Executive of Chiron Diagnostics, General Manager of IBM’s Worldwide Healthcare Solutions, and led McKinsey & Company’s European healthcare practice.

Celgene’s best-selling product Revlimid suffered a setback in November 2011 when it found in Phase III trials to provide no overall survival benefit to patients with prostate cancer.

Share this article: